Indoco Remedies Limited, India
Author Profile
SCOPUS
🎓 EARLY ACADEMIC PURSUITS
Dr. Sandeep Shidu Zokande began his academic journey with a B.Sc. in Chemistry from Shivaji University in 1991. His deep interest in analytical sciences led him to pursue M.Sc. in Analytical Chemistry from Mumbai University in 1995, culminating in a Ph.D. in Analytical Chemistry from the same prestigious institution in 2001. His early years laid a strong foundation in instrumentation, spectroscopy, and chromatography, which would define his prolific career in pharmaceutical analysis.
🏢 PROFESSIONAL ENDEAVORS
With over 24 years of impactful industry experience, Dr. Zokande has held senior leadership roles across Indoco Analytical Solutions, Indoco Remedies Ltd., Sandoz Pvt. Ltd., S. Zhaveri Pharmachem, Rubicon Research, and WRIC, Mumbai University.
-
Vice President, Indoco Analytical Solutions (Since July 2024): Leads a team of 16 scientists, managing analytical portfolios for oral solids, injectables, ophthalmics, suspensions, and solutions.
-
Vice President, Indoco Remedies Ltd. (2011–2024): Headed a department of 115 scientists, responsible for analytical strategies for over 100 ANDAs and numerous global dossiers.
-
Head, S. Zhaveri Pharmachem (Two terms): Directed method development, validation, and customer communication.
-
Senior Group Analytical Expert, Sandoz (2004–2010): Led a 40-member team for regulatory compliance and method validation.
-
Product Development Officer, Rubicon Research and Project Assistant, WRIC, University of Mumbai: Early roles involved critical method development and national-level training organization.
Dr. Zokande has consistently advanced the field of pharmaceutical analysis, with expertise in:
-
Analytical method development and validation
-
Stability studies, impurity profiling
-
Regulatory submissions (ANDA, EU, ANVISA, TGA)
-
DMF revisions and scientific write-ups
-
Global regulatory compliance & SOP development
-
Laboratory setup and audit readiness
His analytical leadership has played a crucial role in First-To-File (FTF) strategies and reducing regulatory risk through stringent quality control and scientific documentation.
🏅 ACADEMIC CITATIONS, ACCOLADES AND RECOGNITION
-
Reviewer for:
-
USP Monograph Donor Recognition Award (2024)
-
Sandoz “Function of the Year” Awards (2005, 2010)
-
Special MD Award for exemplary leadership during the COVID-19 pandemic
-
Honored by national and international clients for scientific excellence
-
IQAC and Board of Studies member, BNCP College of Pharmacy
-
Guest lecturer, sharing his vast industry insights with future pharma professionals
🌍 IMPACT AND INFLUENCE
-
Leader of teams exceeding 100+ scientists, promoting scientific integrity, efficiency, and talent development.
-
Actively participated in USFDA, EU, ANVISA, and TGA audits, ensuring zero major observations.
-
Mentored the setup of world-class laboratories, including Indoco Remedies, Sandoz Development Centre, and Ratnagiri University sub-centre.
-
Invited panelist at the Express Pharma Analytical Conclave (2022).
-
Business representation in Slovakia, Latvia, and Singapore, promoting Indian pharmaceutical excellence abroad.
🧭 LEGACY AND FUTURE CONTRIBUTIONS
Dr. Zokande’s legacy is one of scientific rigor, visionary leadership, and commitment to global pharmaceutical standards. His future contributions are focused on:
-
Mentorship of next-generation analytical scientists
-
Driving regulatory harmonization and scientific documentation standards
-
Developing green analytical methods and AI-supported analytics
-
Establishing training centers for real-world pharmaceutical skill building
✅CONCLUSION
Dr. Sandeep Shidu Zokande is a pioneering force in pharmaceutical analysis, recognized for his strategic leadership, regulatory expertise, and global impact. From laboratory benches to boardrooms, his career reflects a relentless pursuit of excellence, setting benchmarks in analytical science and regulatory compliance. His legacy will continue to shape India’s pharmaceutical innovation and integrity on the world stage.
🔬NOTABLE PUBLICATION:
Degradation products of nepafenac ophthalmic suspension and accurate structural characterization of 8-benzoyl-1,2-dihydrocinnolin-3(4H)-one through forced degradation and spectral studies
Journal: Results in Chemistry
Year: 2025